Related references
Note: Only part of the references are listed.Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018
Olivier J. Wouters et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Benchmarking biopharmaceutical process development and manufacturing cost contributions to R&D
Suzanne S. Farid et al.
MABS (2020)
Impact of tapering targeted therapies (bDMARDs or JAKis) on the risk of serious infections and adverse events of special interest in patients with rheumatoid arthritis or spondyloarthritis: a systematic analysis of the literature and meta-analysis
D. Vinson et al.
ARTHRITIS RESEARCH & THERAPY (2020)
The search for biosimilars and biobetters
Scott W. Burchiel et al.
DRUG DISCOVERY TODAY (2019)
Charge variants characterization and release assay development for co-formulated antibodies as a combination therapy
Mingyan Cao et al.
MABS (2019)
Risk profiling for a refractory course of rheumatoid arthritis
Manuel Becede et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2019)
Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study
Jacques-Eric Gottenberg et al.
BMJ-BRITISH MEDICAL JOURNAL (2019)
A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501
Richard Markus et al.
ADVANCES IN THERAPY (2019)
Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response
Roy M. Fleischmann et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Biological Characterization of SB3, a Trastuzumab Biosimilar, and the Influence of Changes in Reference Product Characteristics on the Similarity Assessment
Jae Hee Lee et al.
BIODRUGS (2019)
Exploring the analytical power of the QTOF MS platform to assess monoclonal antibodies quality attributes
Ricardo A. Gomes et al.
PLOS ONE (2019)
Glycoform-resolved FcγRIIIa affinity chromatography-mass spectrometry
Steffen Lippold et al.
MABS (2019)
A generic workflow for the characterization of therapeutic monoclonal antibodies-application to daratumumab
Bastiaan L. Duivelshof et al.
ANALYTICAL AND BIOANALYTICAL CHEMISTRY (2019)
Structural Biology of the TNFα Antagonists Used in the Treatment of Rheumatoid Arthritis
Heejin Lim et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
Sizheng Zhao et al.
CURRENT RHEUMATOLOGY REPORTS (2018)
Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis
Laura Chadwick et al.
CURRENT RHEUMATOLOGY REPORTS (2018)
Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications
Nirnoy Dan et al.
PHARMACEUTICALS (2018)
Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies
Qiang Guo et al.
BONE RESEARCH (2018)
Risk of second malignant neoplasm and mortality in patients with rheumatoid arthritis treated with biological DMARDs: a Danish population-based cohort study
Lene Dreyer et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate-to-severe ulcerative colitis
Vandana Midha et al.
INTESTINAL RESEARCH (2018)
Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors
Abril Verden et al.
DRUG SAFETY (2018)
A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy
Paul Emery et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study
Sang-Cheol Bae et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Physicochemical and biological characterization of SB2, a biosimilar of Remicade® (infliximab)
Juyong Hong et al.
MABS (2017)
Novel treatment strategies in rheumatoid arthritis
Gerd R. Burmester et al.
LANCET (2017)
Model-based analysis of N-glycosylation in Chinese hamster ovary cells
Frederick J. Krambeck et al.
PLOS ONE (2017)
Monoclonal antibodies expression improvement in CHO cells by PiggyBac transposition regarding vectors ratios and design
Samira Ahmadi et al.
PLOS ONE (2017)
Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis
K. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
Biosimilars: Key regulatory considerations and similarity assessment tools
Carol F. Kirchhoff et al.
BIOTECHNOLOGY AND BIOENGINEERING (2017)
Response to Treatment with TNFα Inhibitors in Rheumatoid Arthritis Is Associated with High Levels of GM-CSF and GM-CSF+ T Lymphocytes
Jonas Bystrom et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2017)
Interrelationships between Infliximab and Recombinant Tumor Necrosis Factor-α in Plasma Using Minimal Physiologically Based Pharmacokinetic Models
Xi Chen et al.
DRUG METABOLISM AND DISPOSITION (2017)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis
Sofia Ramiro et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives
Jennifer Dumont et al.
CRITICAL REVIEWS IN BIOTECHNOLOGY (2016)
Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases
Hannah A. Blair et al.
BIODRUGS (2016)
A prospective, single-centre, randomised study evaluating the clinical, imaging and immunological depth of remission achieved by very early versus delayed Etanercept in patients with Rheumatoid Arthritis (VEDERA)
Raluca B. Dumitru et al.
BMC MUSCULOSKELETAL DISORDERS (2016)
Characterization of Pharmaceutical IgG and Biosimilars Using Miniaturized Platforms and LC-MS/MS
Kerry M. Wooding et al.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2016)
Challenges of glycosylation analysis and control: an integrated approach to producing optimal and consistent therapeutic drugs
Peiqing Zhang et al.
DRUG DISCOVERY TODAY (2016)
Non-TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug A Randomized Clinical Trial
Jacques-Eric Gottenberg et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Evaluation of the structural, physicochemical, and biological characteristics of SB4, a biosimilar of etanercept
Ick Hyun Cho et al.
MABS (2016)
Phage display-derived human antibodies in clinical development and therapy
Andre Frenzel et al.
MABS (2016)
Biosimilars: Rationale and current regulatory landscape
Ewa Olech
SEMINARS IN ARTHRITIS AND RHEUMATISM (2016)
N-Glycosylation Design and Control of Therapeutic Monoclonal Antibodies
Sha Sha et al.
TRENDS IN BIOTECHNOLOGY (2016)
Efficacy and Safety of Subcutaneous Golimumab in Methotrexate-Naive Patients With Rheumatoid Arthritis: Five-Year Results of a Randomized Clinical Trial
Paul Emery et al.
ARTHRITIS CARE & RESEARCH (2016)
Infecções graves em pacientes com artrite reumatoide em uso de anakinra, rituximab ou abatacept: revisão sistemática de estudos observacionais
Vanderlea Poeys Cabral et al.
Revista Brasileira De Reumatologia (2016)
Engineering the surface properties of a human monoclonal antibody prevents self-association and rapid clearance in vivo
Claire L. Dobson et al.
SCIENTIFIC REPORTS (2016)
Key design considerations on comparative clinical efficacy studies for biosimilars: adalimumab as an example
Zhihong Lai et al.
RMD OPEN (2016)
Tocilizumab as monotherapy or combination therapy for treating active rheumatoid arthritis: a meta-analysis of efficacy and safety reported in randomized controlled trials
Xavier M. Teitsma et al.
ARTHRITIS RESEARCH & THERAPY (2016)
Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases
K. Papamichael et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
MAESTRO - multi agent stability prediction upon point mutations
Josef Laimer et al.
BMC BIOINFORMATICS (2015)
Interleukin-6 as a Therapeutic Target
Jean-Francois Rossi et al.
CLINICAL CANCER RESEARCH (2015)
A Patient With Rheumatoid Arthritis on Methotrexate and Etanercept Who Developed Pasteurella multocida Bacteremia
Jessica Baer Mears et al.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY (2015)
Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study
Yoon Suk Jung et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2015)
Comparison of methods for the analysis of therapeutic immunoglobulin G Fc-glycosylation profiles-Part 2: Mass spectrometric methods
Dietmar Reusch et al.
MABS (2015)
Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis
Tsutomu Takeuchi et al.
MODERN RHEUMATOLOGY (2015)
Biosimilars in rheumatology: current perspectives and lessons learnt
Thomas Doerner et al.
NATURE REVIEWS RHEUMATOLOGY (2015)
Clinical trial development for biosimilars
Rieke Alten et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2015)
Novel therapeutic targets in rheumatoid arthritis
Marije I. Koenders et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2015)
Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials
V. P. Bykerk et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab
M. Neovius et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period
Paul Emery et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study
P. Emery et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Etanercept biosimilars
Valderilio F. Azevedo et al.
RHEUMATOLOGY INTERNATIONAL (2015)
Biosimilars in rheumatology: what the clinician should know
Gilberto Castaneda-Hernandez et al.
RMD OPEN (2015)
Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis
Cecile Gaujoux-Viala et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Small-molecule therapeutics in rheumatoid arthritis: Scientific rationale, efficacy and safety
Florian M. P. Meier et al.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2014)
Managing Patients with Psoriatic Disease: The Diagnosis and Pharmacologic Treatment of Psoriatic Arthritis in Patients with Psoriasis
Philip J. Mease et al.
DRUGS (2014)
Biosimilars in the therapy of inflammatory bowel diseases
Tibor Hlavaty et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2014)
Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs - a systematic review and network meta-analysis
Jeroen P. Jansen et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2014)
Biopharmaceuticals for rheumatic diseases in Latin America, Europe, Russia, and India: Innovators, biosimilars, and intended copies
Gilberto Castaneda-Hernandez et al.
JOINT BONE SPINE (2014)
Physicochemical characterization of Remsima®
Soon Kwan Jung et al.
MABS (2014)
Controllability Analysis of Protein Glycosylation in Cho Cells
Melissa M. St Amand et al.
PLOS ONE (2014)
Biosimilars in rheumatology: perspective and concerns
Morton A. Scheinberg et al.
RHEUMATOLOGY (2014)
Protein kinase small molecule inhibitors for rheumatoid arthritis: Medicinal chemistry/clinical perspectives
Charles J. Malemud et al.
WORLD JOURNAL OF ORTHOPEDICS (2014)
Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: persistence and dosing patterns in Germany
Sarah Neubauer et al.
HEALTH ECONOMICS REVIEW (2014)
Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseases
M. Rinaudo-Gaujous et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
Biosimilars to treat inflammatory arthritis: the challenge of proving identity
Jonathan Kay et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Biosimilars in rheumatology: the wind of change
Christian K. Schneider
ANNALS OF THE RHEUMATIC DISEASES (2013)
A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study
Dae Hyun Yoo et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study
Won Park et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Targeting kinases: a new approach to treating inflammatory rheumatic diseases
David L. Simmons
CURRENT OPINION IN PHARMACOLOGY (2013)
Approval of the first biosimilar antibodies in Europe A major landmark for the biopharmaceutical industry
Alain Beck et al.
MABS (2013)
Characterization of N-Linked Glycosylation in a Monoclonal Antibody Produced in NS0 Cells Using Capillary Electrophoresis with Laser-Induced Fluorescence Detection
Melissa Hamm et al.
PHARMACEUTICALS (2013)
Comparison of the efficacy and safety of Rituximab (Mabthera™) and its biosimilar (Reditux™) in diffuse large B-cell lymphoma patients treated with chemo-immunotherapy: A retrospective analysis
Partha Sarathi Roy et al.
INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY (2013)
Biosimilar, Biobetter, and Next Generation Antibody Characterization by Mass Spectrometry
Alain Beck et al.
ANALYTICAL CHEMISTRY (2012)
The State of the Art in the Development of Biosimilars
Mark McCamish et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Lectins: production and practical applications
Sze Kwan Lam et al.
APPLIED MICROBIOLOGY AND BIOTECHNOLOGY (2011)
The burden of illness of rheumatoid arthritis
Annelies Boonen et al.
CLINICAL RHEUMATOLOGY (2011)
The economic burden of rheumatoid arthritis: beyond health care costs
Wei Zhang et al.
CLINICAL RHEUMATOLOGY (2011)
Anti-TNF Treatment in Rheumatoid Arthritis
Janina Geiler et al.
CURRENT PHARMACEUTICAL DESIGN (2011)
Acceptable changes in quality attributes of glycosylated biopharmaceuticals
Martin Schiestl et al.
NATURE BIOTECHNOLOGY (2011)
Biosimilars-why terminology matters
Martina Weise et al.
NATURE BIOTECHNOLOGY (2011)
MECHANISMS OF DISEASE The Pathogenesis of Rheumatoid Arthritis
Iain B. McInnes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Blockade of TNF-α rapidly inhibits pain responses in the central nervous system
Andreas Hess et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Societal cost of rheumatoid arthritis patients in the US
Howard Birnbaum et al.
CURRENT MEDICAL RESEARCH AND OPINION (2010)
DRUG DEVELOPMENT 'Biosimilar' drugs poised to penetrate market
Heidi Ledford
NATURE (2010)
India's Cipla sets sights on Avastin, Herceptin and Enbrel
Killugudi Jayaraman
NATURE BIOTECHNOLOGY (2010)
Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial
J. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials
C. Salliot et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study
E. C. Keystone et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Effect of Certolizumab Pegol With Methotrexate on Home and Work Place Productivity and Social Activities in Patients With Active Rheumatoid Arthritis
Arthur Kavanaugh et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2009)
Golimumab, a New Human Tumor Necrosis Factor α Antibody, Administered Every Four Weeks as a Subcutaneous Injection in Psoriatic Arthritis Twenty-Four-Week Efficacy and Safety Results of a Randomized, Placebo-Controlled Study
Arthur Kavanaugh et al.
ARTHRITIS AND RHEUMATISM (2009)
Golimumab, a Human Anti-Tumor Necrosis Factor α Monoclonal Antibody, Injected Subcutaneously Every Four Weeks in Methotrexate-Naive Patients With Active Rheumatoid Arthritis Twenty-Four-Week Results of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Golimumab Before Methotrexate as First-Line Therapy for Early-Onset Rheumatoid Arthritis
Paul Emery et al.
ARTHRITIS AND RHEUMATISM (2009)
Incidence and nature of infectious disease in patients treated with anti-TNF agents
Siba P. Raychaudhuri et al.
AUTOIMMUNITY REVIEWS (2009)
Population Pharmacokinetics of Golimumab, an Anti-Tumor Necrosis Factor-alpha Human Monoclonal Antibody, in Patients With Psoriatic Arthritis
Zhenhua Xu et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis
Roger Palframan et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2009)
Golimumab inpatients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial
Josef S. Smolen et al.
LANCET (2009)
Latent Infection and Tuberculosis Disease in Rheumatoid Arthritis Patients
Eduardo Acevedo-Vasquez et al.
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA (2009)
Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action
Royston Jefferis
TRENDS IN PHARMACOLOGICAL SCIENCES (2009)
When patients with rheumatoid arthritis fail tumour necrosis factor inhibitors: what is the next step?
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Tumour necrosis factor blockade increases lymphangiogenesis in murine and human arthritic joints
K. Polzer et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate
M. Schiff et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Certolizumab Pegol Plus Methotrexate Is Significantly More Effective Than Placebo Plus Methotrexate in Active Rheumatoid Arthritis Findings of a Fifty-Two-Week, Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study
Edward Keystone et al.
ARTHRITIS AND RHEUMATISM (2008)
Efficacy and Safety of Golimumab in Patients With Ankylosing Spondylitis Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial
Robert D. Inman et al.
ARTHRITIS AND RHEUMATISM (2008)
DMARDS and infections in rheumatoid arthritis
Roberto Caporali et al.
AUTOIMMUNITY REVIEWS (2008)
Novel approaches for the treatment of rheumatoid arthritis: lessons from the evaluation of synovial biomarkers in clinical trials
Danielle M. Gerlag et al.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2008)
The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis
George D. Kalliolias et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2008)
Therapeutic targeting of Janus kinases
Marko Pesu et al.
IMMUNOLOGICAL REVIEWS (2008)
Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial
Paul Emery et al.
LANCET (2008)
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
Daniel Tracey et al.
PHARMACOLOGY & THERAPEUTICS (2008)
New therapies for treatment of rheumatoid arthritis
Josef S. Smolen et al.
LANCET (2007)
Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti-tumor necrosis factor at agents
Andrew Nesbitt et al.
INFLAMMATORY BOWEL DISEASES (2007)
Cytokines in the pathogenesis of rheumatoid arthritis
Iain B. McInnes et al.
NATURE REVIEWS IMMUNOLOGY (2007)
Cytokines, Inflammation, and Pain
Jun-Ming Zhang et al.
INTERNATIONAL ANESTHESIOLOGY CLINICS (2007)
Measuring the burden of disease in Korea
Seok-Jun Yoon et al.
JOURNAL OF KOREAN MEDICAL SCIENCE (2007)
Current and future issues in the manufacturing and development of monoclonal antibodies
Steven Kozlowski et al.
ADVANCED DRUG DELIVERY REVIEWS (2006)
The impact of rheumatoid arthritis on medical expenditures, absenteeism, and short-term disability benefits
RJ Ozminkowski et al.
JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE (2006)
The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
FC Breedveld et al.
ARTHRITIS AND RHEUMATISM (2006)
PEGylation, successful approach to drug delivery
FM Veronese et al.
DRUG DISCOVERY TODAY (2005)
Cytokine networks - towards new therapies for rheumatoid arthritis
IB McInnes et al.
NATURE CLINICAL PRACTICE RHEUMATOLOGY (2005)
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study) - A randomized, controlled trial
YPM Goekoop-Ruiterman et al.
ARTHRITIS AND RHEUMATISM (2005)
Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer
S Madhusudan et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Interaction between synovial inflammatory tissue and bone marrow in rheumatoid arthritis
E Jimenez-Boj et al.
JOURNAL OF IMMUNOLOGY (2005)
Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin
K Raza et al.
ARTHRITIS RESEARCH & THERAPY (2005)
Adalimumab therapy in rheumatoid arthritis
E Keystone et al.
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA (2004)
The use of TNF-α blocking agents in rheumatoid arthritis:: an overview
É Toussirot et al.
EXPERT OPINION ON PHARMACOTHERAPY (2004)
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial
L Klareskog et al.
LANCET (2004)
Rheumatoid fibroblast-like synoviocytes overexpress the chemokine stromal cell-derived factor 1 (CXCL12), which supports distinct patterns and rates of CD4+ and CD8+ T cell migration within synovial tissue
PF Bradfield et al.
ARTHRITIS AND RHEUMATISM (2003)
Therapeutic strategies for rheumatoid arthritis
JS Smolen et al.
NATURE REVIEWS DRUG DISCOVERY (2003)
Proteomic analysis of post-translational modifications
M Mann et al.
NATURE BIOTECHNOLOGY (2003)
The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity
T Shinkawa et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
PEGylated antibodies and antibody fragments for improved therapy: a review
AP Chapman
ADVANCED DRUG DELIVERY REVIEWS (2002)
Analysis of cytokine expression in rheumatoid synovium has provided new insights into the pathogenesis of rheumatoid arthritis and new therapeutic opportunities
M Feldmann et al.
TRANSPLANTATION PROCEEDINGS (2001)
A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis
JM Bathon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Economic burden of rheumatoid arthritis: a systematic review
NJ Cooper
RHEUMATOLOGY (2000)
Share Paper
